Home/Pipeline/SILENOR

SILENOR

Insomnia

ApprovedActive

Key Facts

Indication

Insomnia

Phase

Approved

Status

Active

Company

Currax Pharmaceuticals

About Currax Pharmaceuticals

Currax Pharmaceuticals is a commercial-stage biopharma company that has built a portfolio of marketed products, most notably the obesity drug CONTRAVE®. The company leverages a business model of acquiring and commercializing established or niche pharmaceutical products, with a significant strategic focus on the obesity treatment market. Under CEO George Hampton, Currax emphasizes direct-to-patient platforms, educational campaigns, and ensuring supply chain resilience to compete in the dynamic chronic disease landscape.

View full company profile

Therapeutic Areas

Obesity Migraine Insomnia Pain

Other Insomnia Drugs

Drug	Company	Phase	Status
Cannabidiol Soft‑Gel Capsule	Avecho Biotechnology	Phase 3	Active
Nexalin Device	Nexalin Technology	Pivotal Trial	Active
CLM-IN01	Closed Loop Medicine	Pre-commercial (UKCA/CE marked)	Active
Levroso Long (Diphenhydramine/Melatonin)	NovaMedica	Approved	Active
Insomnia Studies	Pacific Clinical Research Medical Group	Phase 2/3	Active
HS-10384	Hansoh Pharma	Phase III	Active
CEL-101 (C-122)	Celon Pharma	Phase II	Active
CGS-2	Canopy Growth	Phase II	Active, Recruiting